Börje Ljungberg from Umeå University Sweden discusses the Development of Guidelines in a Rapidly Changing Treatment Landscape for the John Fitzpatrick Memorial Lecture at the 12th European International Kidney Cancer Symposium 2017.
Author: Editor
Bernard Escudier of the Gustave Roussy discusses Brain mets under I.O. at the 12th European International Kidney Cancer Symposium 2017
Guillermo de Velasco MD, PhD University Hospital 12 de Octubre discusses SBRT for lung metastases: Case report at the 12th European International Kidney Cancer Symposium 2017
Manuela Schmidinger of the Medical University of Vienna discusses the Solitary Bone Mets Spinal at the 12th European International Kidney Cancer Symposium 2017
Camillo Porta, MD of the I.R.C.C.S. San Matteo University Hospital Foundation answers the question How should the next generation of trials address the question of the sequence? at the 12th European International Kidney Cancer Symposium 2017
Gabriel Malouf, MD, PhD of Pitié-Salpêtrière Hospital Defines Optimal 2nd Line Treatment and Sequence: Biomarker at the 12th European International Kidney Cancer Symposium 2017
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Eric P. Winer looks back at the advances made in the treatment of breast cancer in the last few decades in an effort to elucidate how to best move forward in 2017. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Dawn L. Hershman discusses the latest insights in breast cancer prevention, survivorship, and health care delivery. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Constantine Godellas discusses the latest advances in local-regional approaches for the treatment of breast cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
David McDermott, MD of the Dana-Farber/Harvard Cancer Center outlines and Defines Optimal 2nd Line Treatment and Sequence: Subgroup Analysis from Pivotal Studies and Real World Data at the  12th European International Kidney Cancer Symposium 2017
John B.A.G. Haanen MD PhD of the The Netherlands Cancer Institute discusses Anti-PD1 PDL1 + anti-VEGFR in Kidney Cancer at the  12th European International Kidney Cancer Symposium 2017
Toni K. Choueiri, MD of the Dana-Farber Cancer Institute discusses the changes in first line kidney cancer treatment for 2018 at the  12th European International Kidney Cancer Symposium 2017
Thomas Powles MD of Barts Cancer Institute discusses the Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients at the  12th European International Kidney Cancer Symposium 2017
Hans Hammers, MD, PhD, UT Southwestern discusses the Dual Immune Checkpoint Blockade at the  12th European International Kidney Cancer Symposium 2017
Alain Ravaud, MD.PhD takes the pro side of the debate entitled Adjuvant Therapy Ready For Prime Time In Kidney Cancer at the  12th European International Kidney Cancer Symposium
Tanja de Gruijl, VU University Medical Center discusses Harnessing the sentinel lymph node Translational perspective: LN as the first priming site of the immune system at the  12th European International Kidney Cancer Symposium 2017
Prof. Dr. med. Viktor Grünwald of the Medical School Hannover outlines the Oncologists perspective LN as metastatic spread at the  12th European International Kidney Cancer Symposium 2017
Jose A. Karam, MD, FACS, Associate Professor Department of Urology MD Anderson Cancer Center discusses Surgeons Perspective: LN as a Draining Pattern from the 12th European International Kidney Cancer Symposium 2017
Aung Naing of MD Anderson Cancer Center discusses PEGylated Human IL-10 AM0010 in Combination with Nivolumab in Renal Cell Cancer at the  12th European International Kidney Cancer Symposium 2017
Cynthia Macahilig of the University of Manchester discusses Health-Related Quality of Life, Treatment Satisfaction, and Work Productivity for Patients With Advanced Renal Cell Carcinoma in a Chart Review Across Six Countries  12th European International Kidney Cancer Symposium 2017
Hans J. Hammers, MD of the University of Texas Southwestern Medical Center discusses Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study from the  12th European International Kidney Cancer Symposium 2017
Krzysztof Krawczyk of the Department of Translational Medicine, Center for Molecular Pathology Lund University, Malmö, Sweden discusses the papillary renal cell carcinoma-derived chemerin, IL-8 and CXCL16 attract and differentiate monocytes at the  12th European International Kidney Cancer Symposium 2017
Saeed Dabestani MD PhD student Lund University, Sweden discusses the Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes a RECUR database analysis at the  12th European International Kidney Cancer Symposium 2017
Axel Bex, MD, PhD, of The Netherlands Cancer Institute in Amsterdam discusses the Challenges in Surgical Trials for Kidney Cancer at the  12th European International Kidney Cancer Symposium
In this activity, meeting co-chair Dr. John P. Leonard provides the key take-home messages from the leukemia, myeloid disorders, and benign hematology sessions at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7254 © 2017 Imedex, LLC.
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Kathy S. Albain discusses updates in adjuvant and neoadjuvant therapy for the treatment of breast cancer, and elaborates on the latest data on predictors of benefit. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Debu Tripathy discusses novel therapeutics for the treatment of breast cancer, with a focus on HER2+ and triple negative disease. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Hope S. Rugo discusses novel therapeutics for the treatment of breast cancer, with a focus on CDK inhibitors, immunotherapy, and the role of tumor infiltrating lymphocytes. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
In this activity, meeting co-chair Dr. David P. Steensma provides the key take-home messages from the leukemia, myeloid disorders, and benign hematology sessions at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7253 © 2017 Imedex, LLC.
In this activity, meeting co-chair Dr. Robert Z. Orlowski provides the key take-home messages from the plasma cell disorder session at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7252 © 2017 Imedex, LLC.
Dr. Arnaud Mejean, MD presents the challenges in CARMENA from the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany
Dr. Thomas Powles, MD presents the Challenges in Neoadjuvant Biomarker Trials at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany.
Axel Bex, MD presents Challenges In Surtime at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany    kidney cancer, challenges in surtime Â
Dr. Cora Sternberg, MD presents the P.H.M. deMulder Lecture entitled From cytokines to targeted therapies to immunotherapy30 years of progress in advanced RCC at the 12th Annual 2017 Kidney Cancer European Meeting in Munich, Germany.
Bernard J. Escudier, MD introduces Dr. Cora Sternberg, MD before the P.J.M. dMulder Lecture at the 12th Annual European Kidney Cancer Meeting 2017
Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the treatment trends for lymphoma in 2017, which include targeted therapy, chemotherapy, and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an overview of his presentation, CHRONOS-1, which shows the use of copanlisib in B-Cell Lymphoma patients. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC. CORRECTION: Follicular Lymphoma subset ORR was 59.7% MZL group was 69.6%
Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an update on immunotherapy, which was a hot topic of AACR 2017. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Martin Dreyling, MD of University of Munich Hospital in Grosshadern explains the difference between copanlisib and other PI3K inhibitors, specifically Idelalisib He argues that copanlisib seems to be better tolerated in patients than Idelalisib. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the impact of his clinical trial, CHRONOS-1, on current and future cancer research. He states that the compounds of drugs are affective in any stage of disease and that the data continues to show the important roles of PI3K Inhibitors. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the treatment trends in 2017 for his field, neuro-oncology, which include more use of checkpoint inhibitors and combination therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of the AACR presentations, which show more data and focus on exosomes and blood biopsies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how intracellular targets are detected onto the cell surface. He states that this target is a protein that usually does not belong on the cell surface, but has been detected through an antibody. The uncertainty of how this target moved is part of exciting new research in glioma biology. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how the clinical data will help better characterize which patients respond to immunotherapy. Specifically, this data would tell clinicians which patients respond to the survivin vaccine. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the impact his clinical trial has on clinicians and future research. He states that if they continue to build more data, then the study could potentionally predict when a patient may recur. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Circulating CD9-GFAP-survivin exosomes during active specific immunotherapy, a potential biomarker for glioma, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives her input on when patients should stop treatment. She states that if the patient shows responsive to treatment, then she would feel comfortable allowing the patient to stop early. She also explains whether or not all patients should have PD-L1 staining. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains how this clinical trial now allows clinicians and other healthcare professionals to quote five-year data to patients with non-small cell lung cancer. She argues the impact of this data will give hope to lung cancer patients of their options. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center discusses the treatment trends for 2017 in thoracic oncology. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of her presentation which discussed a five-year follow-up of Lung Cancer patients, who were treated with Nivolumab. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.